Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 18/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 18/20 | 0.70 |
| ▸ | HDAC7 | Q8WUI4 | 18/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 18/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.70 |
| ▸ | EGFR | P00533 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722466 | 0.89 | HDAC3 (0.69) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| SCHEMBL1683598 | 0.89 | HDAC3 (0.69) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| SCHEMBL1683629 | 0.89 | EGFR (0.69) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| SCHEMBL1683637 | 0.88 | HDAC3 (0.67) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| SCHEMBL1683696 | 0.88 | HDAC3 (0.67) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| SCHEMBL786715 | 0.88 | HDAC3 (0.67) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| SCHEMBL3466531 | 0.88 | EGFR (0.72) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| SCHEMBL20850974 | 0.88 | HDAC3 (0.67) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| SCHEMBL1683710 | 0.88 | HDAC3 (0.67) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| SCHEMBL723752 | 0.88 | HDAC3 (0.67) | HDAC3HDAC1HDAC7HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303021-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER | UNIV TENNESSEE RES FOUND (US) | 2018-12-19 | — | — | EP | claimed |
| CN-102137592-B | Compounds for the treatment of cancer | UNIV TENNESSEE RES FOUNDATION (US) | 2015-01-28 | — | — | CN | claimed |
| US-8592465-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-11-26 | — | — | US | claimed |
| EP-2303021-A2 | COMPOUNDS FOR THE TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2011-04-06 | — | — | EP | claimed |
| WO-2010074776-A2 | COMPOUNDS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-07-01 | — | — | WO | claimed |
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2009-12-31 | — | — | US | claimed |
| EP-3289876-B1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIV TENNESSEE RES FOUND (US) | 2022-07-20 | — | — | EP | disclosed |
| US-10865196-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-12-15 | — | — | US | disclosed |
| US-10301285-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2019-03-28 | — | — | US | disclosed |
| EP-2303021-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER | UNIV TENNESSEE RES FOUND (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2018-04-05 | — | — | US | disclosed |
| EP-3289876-A1 | COMPOUNDS FOR TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9029408-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| CN-102137592-B | Compounds for the treatment of cancer | UNIV TENNESSEE RES FOUNDATION (US) | 2015-01-28 | — | — | CN | disclosed |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8592465-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2303021-A2 | COMPOUNDS FOR THE TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010074776-A2 | COMPOUNDS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | HCCS, NQO1, CCNY | HDAC3 569/4885HDAC1 287/4885HDAC7 661/4885 |
| US-10865196-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | HDAC3 1097/4885HDAC1 1044/4885HDAC7 313/4885 |
| US-10301285-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | HDAC3 1097/4885HDAC1 1044/4885HDAC7 313/4885 |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | HDAC3 1097/4885HDAC1 1044/4885HDAC7 313/4885 |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | HDAC3 1097/4885HDAC1 1044/4885HDAC7 313/4885 |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | HDAC3 1097/4885HDAC1 1044/4885HDAC7 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.